Shopping Cart
Remove All
Your shopping cart is currently empty
Anti-Mouse IFN gamma Antibody (XMG1.2) is an inhibitory antibody that targets and neutralizes mouse IFN-γ, suitable for research in cancer, inflammation, and immunology.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $73 | - | In Stock | |
| 5 mg | $263 | - | In Stock | |
| 10 mg | Preferential | 2-4 weeks | 2-4 weeks |
| Description | Anti-Mouse IFN gamma Antibody (XMG1.2) is an inhibitory antibody that targets and neutralizes mouse IFN-γ, suitable for research in cancer, inflammation, and immunology. |
| In vivo | Anti-Mouse IFN gamma Antibody (XMG1.2) (500 μg; intraperitoneal injection; administered on days 0/3/7/10/14/17) increased the incidence and severity of multiple myeloma in a mouse model, indicating IFNγ as a mediator of successful anti-myeloma immune responses in the 5TGM1 metastasis model [1]. Anti-Mouse IFN gamma Antibody (XMG1.2) is effective in a mouse model of hemophagocytic lymphohistiocytosis secondary to chronic inflammation [2]. Anti-Mouse IFN gamma Antibody (XMG1.2) (100 mg/kg; intravenous injection; administered on days 14/20/28/35/42) improved graft implantation in Ifngr1-/- mice infected with BCG [3]. Anti-Mouse IFN gamma Antibody (XMG1.2) (100 μg; intraperitoneal injection; administered every other day starting on day 10) prevented Purkinje cell loss and clinical disease in a mouse model of paraneoplastic cerebellar degeneration [4]. Anti-Mouse IFN gamma Antibody (XMG1.2) (100 µg/g; intraperitoneal injection; single dose) increased survival in an LPS-induced macrophage activation syndrome mouse model[5]. Anti-Mouse IFN gamma Antibody (XMG1.2) (500 μg; intraperitoneal injection; administered on days 0/3/7/10/14/17) increased the incidence and severity of multiple myeloma in a mouse model, indicating IFNγ as a mediator of successful anti-myeloma immune responses in the 5TGM1 metastasis model [1]. Anti-Mouse IFN gamma Antibody (XMG1.2) is effective in a mouse model of hemophagocytic lymphohistiocytosis secondary to chronic inflammation [2]. Anti-Mouse IFN gamma Antibody (XMG1.2) (100 mg/kg; intravenous injection; administered on days 14/20/28/35/42) improved graft implantation in Ifngr1-/- mice infected with BCG [3]. Anti-Mouse IFN gamma Antibody (XMG1.2) (100 μg; intraperitoneal injection; administered every other day starting on day 10) prevented Purkinje cell loss and clinical disease in a mouse model of paraneoplastic cerebellar degeneration [4]. Anti-Mouse IFN gamma Antibody (XMG1.2) (100 µg/g; intraperitoneal injection; single dose) increased survival in an LPS-induced macrophage activation syndrome mouse model[5]. |
| Clone | XMG1.2 |
| Reactivity | Mouse |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | IFNγ |
| Molecular Weight | 150 kDa |
| Isotype | Rat IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.